Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ningning Hou

Showing results (31-40 of 90) with videos related to

Pageof 9
Sort By:
Clinical and Experimental Pharmacology & Physiology|September 14, 2017
C1q/TNF-related protein 9 improves the anti-contractile effects of perivascular adipose tissue via the AMPK-eNOS pathway in diet-induced obese miceFang Han, Yang Zhang, Mingxia Shao, et al.
BMJ Open|March 17, 2023
Secular trends of epidemiologic patterns of chronic kidney disease over three decades: an updated analysis of the Global Burden of Disease Study 2019Xiaojin Feng, Ningning Hou, Zhenna Chen, et al.
Phytotherapy Research : PTR|July 8, 2025
Therapeutic Potential of Ginsenosides in the Treatment of Endocrine Diseases: Roles and MechanismsJing Li, Hongyan Qiu, Xiaoxiao Liu, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|February 8, 2026
Micro- and Nanoplastics and PM2.5 in Cardiovascular Disease: Emerging Mechanisms, Impacts, and Therapeutic InsightsSilin Kong, Kexin Zhang, Jiajun Sang, et al.
European Journal of Gastroenterology & Hepatology|December 4, 2025
Epidemiology of metabolic dysfunction-associated steatotic liver disease -related liver diseases: 1990-2021 and projections to 2045Chengxia Kan, Kexin Zhang, Ningning Hou, et al.
Journal of Anxiety Disorders|March 21, 2026
Trends and determinants of childhood anxiety disorders burden in Asia, 1990-2023Kexin Zhang, Chengxia Kan, Fang Han, et al.
Life Sciences|June 11, 2024
Emerging therapeutic landscape: Incretin agonists in chronic kidney disease managementKexin Lian, Kexin Zhang, Chengxia Kan, et al.
Frontiers in Pharmacology|January 7, 2022
Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver DiseaseYuting Ma, Chengxia Kan, Hongyan Qiu, et al.
Clinical and Experimental Pharmacology & Physiology|August 7, 2020
Liraglutide improves obesity-induced renal injury by alleviating uncoupling of the glomerular VEGF-NO axis in obese miceKai Li, Jinhong Sun, Na Huang, et al.
American Journal of Physiology. Endocrinology and Metabolism|October 6, 2025
Ribosome collisions and ZAKα activation: explores the therapeutic potential of metabolic diseasesWenqiang Zhang, Kexin Zhang, Chengxia Kan, et al.
Pageof 9

Showing results (31-40 of 90) with videos related to

Sort By:
Pageof 9
Clinical and Experimental Pharmacology & Physiology|September 14, 2017
C1q/TNF-related protein 9 improves the anti-contractile effects of perivascular adipose tissue via the AMPK-eNOS pathway in diet-induced obese miceFang Han, Yang Zhang, Mingxia Shao, et al.
BMJ Open|March 17, 2023
Secular trends of epidemiologic patterns of chronic kidney disease over three decades: an updated analysis of the Global Burden of Disease Study 2019Xiaojin Feng, Ningning Hou, Zhenna Chen, et al.
Phytotherapy Research : PTR|July 8, 2025
Therapeutic Potential of Ginsenosides in the Treatment of Endocrine Diseases: Roles and MechanismsJing Li, Hongyan Qiu, Xiaoxiao Liu, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|February 8, 2026
Micro- and Nanoplastics and PM2.5 in Cardiovascular Disease: Emerging Mechanisms, Impacts, and Therapeutic InsightsSilin Kong, Kexin Zhang, Jiajun Sang, et al.
European Journal of Gastroenterology & Hepatology|December 4, 2025
Epidemiology of metabolic dysfunction-associated steatotic liver disease -related liver diseases: 1990-2021 and projections to 2045Chengxia Kan, Kexin Zhang, Ningning Hou, et al.
Journal of Anxiety Disorders|March 21, 2026
Trends and determinants of childhood anxiety disorders burden in Asia, 1990-2023Kexin Zhang, Chengxia Kan, Fang Han, et al.
Life Sciences|June 11, 2024
Emerging therapeutic landscape: Incretin agonists in chronic kidney disease managementKexin Lian, Kexin Zhang, Chengxia Kan, et al.
Frontiers in Pharmacology|January 7, 2022
Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver DiseaseYuting Ma, Chengxia Kan, Hongyan Qiu, et al.
Clinical and Experimental Pharmacology & Physiology|August 7, 2020
Liraglutide improves obesity-induced renal injury by alleviating uncoupling of the glomerular VEGF-NO axis in obese miceKai Li, Jinhong Sun, Na Huang, et al.
American Journal of Physiology. Endocrinology and Metabolism|October 6, 2025
Ribosome collisions and ZAKα activation: explores the therapeutic potential of metabolic diseasesWenqiang Zhang, Kexin Zhang, Chengxia Kan, et al.
Pageof 9